Entera Bio (NASDAQ:ENTX) Research Coverage Started at Leerink Partners

Leerink Partners started coverage on shares of Entera Bio (NASDAQ:ENTX) in a research report report published on Friday morning, Marketbeat.com reports. The firm issued an outperform rating and a $9.00 target price on the stock.

Several other analysts have also weighed in on the company. Wall Street Zen upgraded Entera Bio to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.00.

Entera Bio Stock Performance

Shares of NASDAQ ENTX opened at $2.96 on Friday. Entera Bio has a 12-month low of $0.91 and a 12-month high of $4.20. The firm’s 50-day moving average price is $2.79 and its 200-day moving average price is $1.82. The stock has a market capitalization of $514.54 million, a price-to-earnings ratio of -8.46 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06).

Institutional Investors Weigh In On Entera Bio

A hedge fund recently raised its position in Entera Bio stock. Renaissance Technologies LLC grew its stake in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 338.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 473,442 shares of the company’s stock after purchasing an additional 365,441 shares during the quarter. Renaissance Technologies LLC owned approximately 0.96% of Entera Bio worth $526,000 at the end of the most recent quarter. 14.11% of the stock is currently owned by institutional investors.

About Entera Bio

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.